Idiopathic Fecal Incontinence Clinical Trial
The purpose of this study is to assess the effect and safety of alpha agonist ointment on fecal incontinence severity in patients with idiopathic fecal incontinence.
This is a double blinded cross over study. Approximately 40 subjects will be participating
in this 4 weeks study. A screening visit will be used to determine eligibility for the
study. Patients found eligible will receive alpha agonist ointment or placebo ointment for 2
weeks. This will be followed by a second 2 weeks treatment cycle in which:
- patients previously treated with alpha agonist will be treated with placebo.
- patients previously treated with placebo will be treated with alpha agonist.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment